Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


Articles published in Int J Radiat Oncol Biol Phys

Retrieve available abstracts of 320 articles:
HTML format



Single Articles


    April 2024
  1. VITZTHUM LK, Surucu M, Gensheimer MF, Kovalchuk N, et al
    BIOGUIDE-X: A First-in-Human Study of the Performance of Positron Emission Tomography-Guided Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2024;118:1172-1180.
    PubMed     Abstract available


    March 2024
  2. FAROOQI AS, Yoder AK, Lin HY, Pasalic D, et al
    SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection.
    Int J Radiat Oncol Biol Phys. 2024;118:971-978.
    PubMed     Abstract available


  3. LUCIA F, Bourhis D, Pinot F, Hamya M, et al
    Prediction of Acute Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy Using Dose-Volume Parameters From Functional Mapping on Gallium 68 Perfusion Positron Emission Tomography/Computed Tomography.
    Int J Radiat Oncol Biol Phys. 2024;118:952-962.
    PubMed     Abstract available


  4. LIU YC, Schmidt RO, Kapadia NS, Phillips JD, et al
    Disparities in access to multidisciplinary cancer consultations and treatment for early-stage non-small cell lung cancer patients: A SEER-Medicare analysis.
    Int J Radiat Oncol Biol Phys. 2024 Mar 13:S0360-3016(24)00426.
    PubMed     Abstract available


  5. YAN W, Ren Z, Chen X, Zhang R, et al
    Potential role of lymphocyte CD44 in determining treatment selection between stereotactic body radiotherapy and surgery for early-stage non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2024 Mar 4:S0360-3016(24)00356.
    PubMed     Abstract available


  6. SHUJA M, Owen D
    What if Perioperative Therapy for Non-Small Cell Lung Cancer Renders Someone Inoperable?
    Int J Radiat Oncol Biol Phys. 2024;118:587.
    PubMed    


  7. FARLEY A, Nelson B
    Neoadjuvant Chemoimmunotherapy for Initially Resectable Non-Small Cell Lung Cancer: Queen's Gambit or CheckMate?
    Int J Radiat Oncol Biol Phys. 2024;118:585-586.
    PubMed    


    February 2024
  8. BASCHNAGEL AM, Flakus MJ, Wallat EM, Wuschner AE, et al
    A Phase 2 Randomized Clinical Trial Evaluating 4DCT Ventilation-based Functional Lung Avoidance Radiotherapy for Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2024 Feb 20:S0360-3016(24)00327.
    PubMed     Abstract available


  9. WILLIAMS TM, Miller E, Welliver M, Brownstein J, et al
    A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2024 Feb 20:S0360-3016(24)00324.
    PubMed     Abstract available


  10. HAN C, Qiu J, Bai L, Liu T, et al
    Pneumonitis risk after chemoradiotherapy with and without immunotherapy in patients with locally advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Int J Radiat Oncol Biol Phys. 2024 Feb 13:S0360-3016(24)00298.
    PubMed     Abstract available


  11. KIM H, Lee E, Cho H, Kim E, et al
    Five-Day Spacing of Two Fractionated Ablative Radiotherapies Enhances Antitumor Immunity.
    Int J Radiat Oncol Biol Phys. 2024;118:498-511.
    PubMed     Abstract available


    January 2024
  12. WANG J, Liu Y, Wu D, Tian C, et al
    OTUB1 targets CHK1 for deubiquitinating and stabilizing to facilitate lung cancer progression and radioresistance.
    Int J Radiat Oncol Biol Phys. 2024 Jan 22:S0360-3016(24)00246.
    PubMed     Abstract available


  13. TRAN PT, Mouw KW
    SABR Today . . . and Tomorrow?
    Int J Radiat Oncol Biol Phys. 2024;118:11.
    PubMed    


  14. WRIGHT JL, Bazan JG
    Time to Reconsider the Role of Diagnostic Chest Computed Tomography in Early-Stage Breast Cancer?
    Int J Radiat Oncol Biol Phys. 2024;118:104-106.
    PubMed    


  15. CHEN Y, Pahlavian SH, Jacobs P, Neupane T, et al
    Systematic Evaluation of the Impact of Lung Segmentation Methods on 4-Dimensional Computed Tomography Ventilation Imaging Using a Large Patient Database.
    Int J Radiat Oncol Biol Phys. 2024;118:242-252.
    PubMed     Abstract available


    December 2023
  16. BARTOLOMEO V, Cortiula F, Hendriks LEL, De Ruysscher D, et al
    A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Dec 27:S0360-3016(23)08126.
    PubMed    


  17. RIMNER A, Gelblum DY, Wu AJ, Shepherd AF, et al
    Stereotactic Body Radiation Therapy for Stage IIA to IIIA Inoperable Non-small Cell Lung Cancer - A Phase I Dose Escalation Trial.
    Int J Radiat Oncol Biol Phys. 2023 Dec 26:S0360-3016(23)08252.
    PubMed     Abstract available


  18. RAN X, Wu BX, Shi M, Song L, et al
    CRISPR screen of druggable targets in small cell lung cancer identified ATM inhibitor (AZD1390) as a radiosensitizer.
    Int J Radiat Oncol Biol Phys. 2023 Dec 15:S0360-3016(23)08245.
    PubMed     Abstract available


  19. VAIOS EJ, Shenker RF, Hendrickson PG, Wan Z, et al
    Long-term Intracranial Outcomes with Combination Dual Immune-Checkpoint Blockade and SRS in Patients with Melanoma and NSCLC Brain Metastases.
    Int J Radiat Oncol Biol Phys. 2023 Dec 12:S0360-3016(23)08234.
    PubMed     Abstract available


  20. BASSETTI MF, Morris BA, Sethakorn N, Lang JM, et al
    Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase Ib Trial.
    Int J Radiat Oncol Biol Phys. 2023 Dec 8:S0360-3016(23)08166.
    PubMed     Abstract available


  21. DUDAS D, Saghad PG, Dilling TJ, Perez BA, et al
    Deep Learning-Guided Dosimetry for Mitigating Local Failure of Non-Small Cell Lung Cancer Patients Receiving SBRT.
    Int J Radiat Oncol Biol Phys. 2023 Dec 4:S0360-3016(23)08185.
    PubMed     Abstract available


  22. SAFAVI AH, Palma DA, Giuliani ME
    Beyond the HILUS Trial: How Can We Improve the Safety of SABR for Ultracentral Thoracic Tumors?
    Int J Radiat Oncol Biol Phys. 2023;117:1232-1235.
    PubMed    


  23. SIVA S, Staehler M
    The Right Tool for the Job: The Knife, the SABR, or Fire and Ice?
    Int J Radiat Oncol Biol Phys. 2023;117:1047.
    PubMed    


  24. AHN J, Yeghiaian-Alvandi R, Hegi-Johnson F, Browne LH, et al
    SABR for Early Non-Small Cell Lung Cancer: Changes in Pulmonary Function, Dyspnea, and Quality of Life.
    Int J Radiat Oncol Biol Phys. 2023;117:1213-1221.
    PubMed     Abstract available


  25. LINDBERG S, Grozman V, Karlsson K, Onjukka E, et al
    Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors.
    Int J Radiat Oncol Biol Phys. 2023;117:1222-1231.
    PubMed     Abstract available


  26. LEE SH, Geng H, Arnold J, Caruana R, et al
    Interpretable Machine Learning for Choosing Radiation Dose-volume Constraints on Cardio-pulmonary Substructures Associated with Overall Survival in NRG Oncology RTOG 0617.
    Int J Radiat Oncol Biol Phys. 2023;117:1270-1286.
    PubMed     Abstract available


    November 2023
  27. MA J, Li Y, Yu H, Zhang J, et al
    The Role of Thoracic Vertebral Body Dosimetry in Minimizing Acute Hematologic Toxicities of Non-Small Cell Lung Cancer Patients Receiving Lung Radiotherapy and Immunotherapy.
    Int J Radiat Oncol Biol Phys. 2023 Nov 29:S0360-3016(23)08165.
    PubMed     Abstract available


  28. VALDES G, Scholey J, Nano T, Gennatas ED, et al
    Predicting the impact of proton beam therapy technology on pulmonary toxicities for locally advanced lung cancer patients enrolled on the Proton Collaborative Group prospective clinical trial.
    Int J Radiat Oncol Biol Phys. 2023 Nov 22:S0360-3016(23)08154.
    PubMed     Abstract available


  29. RAMESH S, Cifci A, Javeri S, Minne R, et al
    MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Nov 16:S0360-3016(23)08139.
    PubMed     Abstract available


  30. RITTER AR, Miller ED
    No Regrets About SABR for NETs.
    Int J Radiat Oncol Biol Phys. 2023;117:786.
    PubMed    


  31. OMIDI A, Weiss E, Rosu-Bubulac M, Thomas G, et al
    Quantitative analysis of radiotherapy-induced cardiac and aortic sequelae in lung cancer patients via magnetic resonance imaging: A pilot study.
    Int J Radiat Oncol Biol Phys. 2023 Nov 9:S0360-3016(23)08045.
    PubMed     Abstract available


  32. KUIPERS ME, van Doorn-Wink KCJ, Hiemstra PS, Slats AM, et al
    Predicting radiation-induced lung injury in lung cancer patients - challenges and opportunities: Predicting radiation-induced lung injury.
    Int J Radiat Oncol Biol Phys. 2023 Nov 2:S0360-3016(23)08049.
    PubMed     Abstract available


  33. HEGI-JOHNSON F, Rudd SE, Wichmann CW, Akhurst T, et al
    PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study.
    Int J Radiat Oncol Biol Phys. 2023;117:675-682.
    PubMed    


    October 2023
  34. GAUDREAULT M, Bucknell N, Woon B, Kron T, et al
    Dose-response relationship between radiotherapy and loss of lung perfusion comparing positron emission tomography and dual-energy computed tomography in non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2023 Oct 30:S0360-3016(23)08047.
    PubMed     Abstract available


  35. FRIEDES C, Iocolano M, Lee SH, Li B, et al
    Patterns of Failure, Low Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated with Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors: Patterns of Failure for after PACIFIC.
    Int J Radiat Oncol Biol Phys. 2023 Oct 20:S0360-3016(23)08010.
    PubMed     Abstract available


  36. EDWARDS DM, Sankar K, Alseri A, Jiang R, et al
    Pneumonitis after chemoradiation and adjuvant durvalumab in stage III non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2023 Oct 2:S0360-3016(23)07971.
    PubMed     Abstract available


    September 2023
  37. LIU F, Ververs JD, Farris MK, William Blackstock A Jr, et al
    Optimal Radiotherapy Fractionation Regimens for Early-Stage Non-Small-Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Sep 19:S0360-3016(23)07929.
    PubMed     Abstract available


  38. MENG Y, Sun H, Wang S, Yang H, et al
    Treatment-Related Pneumonitis of EGFR Tyrosine Kinase Inhibitors Plus Thoracic Radiotherapy in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Int J Radiat Oncol Biol Phys. 2023 Sep 14:S0360-3016(23)07917.
    PubMed     Abstract available


  39. LOK BH
    Radiation Therapy in the Molecular Era of Lung Cancer: How Best to Integrate Targeted Therapeutics With Definitive Radiation Therapy for Epidermal Growth Factor Receptor-Mutant Unresectable Stage III Non-Small Cell Lung Cancer?
    Int J Radiat Oncol Biol Phys. 2023;117:115-117.
    PubMed    


  40. OWEN D, Siva S, Salama JK, Daly M, et al
    Some Like It Hot: The Value of Dose and Hot Spots in Lung Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2023;117:1-5.
    PubMed    


  41. PELED N, Roisman LC, Levison E, Dudnik J, et al
    Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study.
    Int J Radiat Oncol Biol Phys. 2023;117:105-114.
    PubMed     Abstract available


    August 2023
  42. YEGYA-RAMAN N, Berman AT, Ciunci CA, Friedes C, et al
    Phase II trial of consolidation pembrolizumab after proton reirradiation for thoracic recurrences of non-small cell lung cancer: Pembro after PBT ReRT for NSCLC.
    Int J Radiat Oncol Biol Phys. 2023 Aug 29:S0360-3016(23)07846.
    PubMed     Abstract available


  43. SIMONE ICB, Serebrenik AA, Gore EM, Mohindra P, et al
    Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients with Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy.
    Int J Radiat Oncol Biol Phys. 2023 Aug 29:S0360-3016(23)07845.
    PubMed     Abstract available


  44. GUAN J, Sun K, Guerrero CA, Zheng J, et al
    A Phase 2 study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Aug 23:S0360-3016(23)07836.
    PubMed     Abstract available


  45. YEGYA-RAMAN N, Friedes C, Lee SH, Iocolano M, et al
    Pneumonitis rates before and after adoption of immunotherapy consolidation in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiation.
    Int J Radiat Oncol Biol Phys. 2023 Aug 22:S0360-3016(23)07815.
    PubMed     Abstract available


  46. HE Y, Cazoulat G, Wu C, Svensson S, et al
    Quantifying the Effect of 4-Dimensional Computed Tomography-Based Deformable Dose Accumulation on Representing Radiation Damage for Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Standard-Fractionated Intensity-Modulated Radiat
    Int J Radiat Oncol Biol Phys. 2023 Aug 7:S0360-3016(23)07648.
    PubMed     Abstract available


  47. THOMSON DJ, Henson C, Huang SH, McDowell LJ, et al
    The Interplay Between Radiation Dose, Volume, and Systemic Therapy.
    Int J Radiat Oncol Biol Phys. 2023;116:967-971.
    PubMed    


    July 2023
  48. OLIVER DE, Laborde JM, Singh DP, Milano MT, et al
    Early-Stage Primary Lung Neuroendocrine Tumors Treated With Stereotactic Body Radiation Therapy: A Multi-Institution Experience.
    Int J Radiat Oncol Biol Phys. 2023;116:849-857.
    PubMed     Abstract available


  49. LADBURY C, Li R, Danesharasteh A, Ertem Z, et al
    Explainable Artificial Intelligence to Identify Dosimetric Predictors of Toxicity in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Secondary Analysis of RTOG 0617.
    Int J Radiat Oncol Biol Phys. 2023 Jul 3:S0360-3016(23)00598.
    PubMed     Abstract available


  50. SIVA S, Solomon BJ
    Metastatic Ablation in Epidermal Growth Factor Receptor Mutated Oligometastatic Non-Small Cell Lung Cancer-Upfront or Outback After Systemic Tyrosine Kinase Inhibitors?
    Int J Radiat Oncol Biol Phys. 2023;116:481-482.
    PubMed    


  51. AMINI A, Rusthoven CG
    Ablative Radiation Therapy for Oligometastatic EGFR-Mutated Non-small Cell Lung Cancer: Who, Why, When, and How?
    Int J Radiat Oncol Biol Phys. 2023;116:481.
    PubMed    


  52. VITZTHUM LK, Pollom EL
    Diverging Roads in the Management of Metastatic EGFR Mutated Non Small Cell Lung Cancer: Ablate All, None, or Some?
    Int J Radiat Oncol Biol Phys. 2023;116:479-480.
    PubMed    


  53. DE B, Andres G, Bates C, Staren E, et al
    Radiation Therapy Expenditures Through the First 8 Performance Periods of the Oncology Care Model at a Statewide Multispecialty Health System.
    Int J Radiat Oncol Biol Phys. 2023;116:491-499.
    PubMed     Abstract available


    May 2023
  54. SIMONE CB, Yegya-Raman N, Manjunath S, Verma V, et al
    Prospective Feasibility and Phase I/II Trial of Preoperative Proton Beam Therapy with Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 May 16:S0360-3016(23)00463.
    PubMed     Abstract available


  55. MORRIS BB, Hughes R, Fields EC, Sabo RT, et al
    Sociodemographic and Clinical Factors Associated With Radiation Treatment Nonadherence and Survival Among Rural and Nonrural Patients With Cancer.
    Int J Radiat Oncol Biol Phys. 2023;116:28-38.
    PubMed     Abstract available


    April 2023
  56. ZHOU R, Qiu B, Xiong M, Liu Y, et al
    Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049).
    Int J Radiat Oncol Biol Phys. 2023 Apr 25:S0360-3016(23)00384.
    PubMed     Abstract available


  57. BUCKNELL NW, Kron T, Herschtal A, Hardcastle N, et al
    Comparison of changes in pulmonary function following stereotactic body radiotherapy versus conventional 3D conformal radiotherapy for stage I and IIa non-small cell lung cancer: an analysis of the TROG 09.02 (CHISEL) phase III trial.
    Int J Radiat Oncol Biol Phys. 2023 Apr 20:S0360-3016(23)00369.
    PubMed     Abstract available


  58. WU TC, Stube A, Felix C, Oseguera D, et al
    Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC).
    Int J Radiat Oncol Biol Phys. 2023 Apr 4:S0360-3016(23)00325.
    PubMed     Abstract available


  59. GREER MD, Koger B, Glenn M, Kang J, et al
    Predicted Inferior Outcomes for Lung SBRT With Treatment Planning Systems That Fail Independent Phantom-Based Audits.
    Int J Radiat Oncol Biol Phys. 2023;115:1301-1308.
    PubMed     Abstract available


  60. STEINSBERGER T, Donetti M, Lis M, Volz L, et al
    Experimental Validation of a Real-Time Adaptive 4D-Optimized Particle Radiotherapy Approach to Treat Irregularly Moving Tumors.
    Int J Radiat Oncol Biol Phys. 2023;115:1257-1268.
    PubMed     Abstract available


  61. MCKENZIE E, Zhang S, Zakariaee R, Guthier CV, et al
    Left Anterior Descending Coronary Artery Radiation Dose Association With All-Cause Mortality in NRG Oncology Trial RTOG 0617.
    Int J Radiat Oncol Biol Phys. 2023;115:1138-1143.
    PubMed     Abstract available


  62. YAMAMOTO T, Kabus S, Bal M, Keall PJ, et al
    Four-Dimensional Computed Tomography Ventilation Image-Guided Lung Functional Avoidance Radiation Therapy: A Single-Arm Prospective Pilot Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2023;115:1144-1154.
    PubMed     Abstract available


    March 2023
  63. KATZ MS, Weissferdt A, Antonoff MB
    Histologic Subtypes of Non-Small Cell Lung Cancer: Can We Further Personalize Radiation Therapy?
    Int J Radiat Oncol Biol Phys. 2023;115:906-908.
    PubMed    


  64. NGUYEN EK, Poon I, Ung YC, Tsao M, et al
    Toxicity and Efficacy of Multitarget Thoracic Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2023;115:897-905.
    PubMed     Abstract available


  65. CANGEMI M, Montico M, Trovo M, Minatel E, et al
    Emerging Role of Immunomonitoring to Predict the Clinical Outcome of Patients With Malignant Pleural Mesothelioma Treated With Radical Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2023;115:608-621.
    PubMed     Abstract available


  66. JOSE SANTO R, Habraken SJM, Breedveld S, Hoogeman MS, et al
    Pencil-beam Delivery Pattern Optimization Increases Dose Rate for Stereotactic FLASH Proton Therapy.
    Int J Radiat Oncol Biol Phys. 2023;115:759-767.
    PubMed     Abstract available


  67. ZHANG Z, Wang Z, Yan M, Yu J, et al
    Radiomics and Dosiomics Signature From Whole Lung Predicts Radiation Pneumonitis: A Model Development Study With Prospective External Validation and Decision-curve Analysis.
    Int J Radiat Oncol Biol Phys. 2023;115:746-758.
    PubMed     Abstract available


    February 2023
  68. NAKAMURA M, Kageyama SI, Hirata H, Tochinai T, et al
    Detection of pretreatment circulating tumor DNA predicts recurrence after high-dose proton beam therapy for early-stage non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2023 Feb 21:S0360-3016(23)00166.
    PubMed     Abstract available


  69. LIVERINGHOUSE CL, Mills MN, Ahmed KA, Washington IR, et al
    Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2023 Feb 14:S0360-3016(22)03689.
    PubMed     Abstract available


    January 2023
  70. SAVLA B, Hamza MA, Yacubovich D, Cobbs S, et al
    The impact of Body Mass Index (BMI) and residence in Food Priority Areas (FPAs) on patterns-of-care and cancer outcomes in patients with stage III non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2023 Jan 28:S0360-3016(23)00080.
    PubMed     Abstract available


  71. LEHRER EJ, Kowalchuk RO, Gurewitz J, Bernstein K, et al
    Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases is not associated with an increased risk of radiat
    Int J Radiat Oncol Biol Phys. 2023 Jan 20:S0360-3016(23)00057.
    PubMed     Abstract available


  72. LIVERINGHOUSE CL, Latifi K, Asous AG, Lam NB, et al
    Dose Limiting Pulmonary Toxicity in a Phase I/II Study of Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for Patients with Stage III Unresectable Non-small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Jan 16:S0360-3016(23)00046.
    PubMed     Abstract available


  73. WANG Y, Zhang T, Wang J, Zhou Z, et al
    Induction Immune Checkpoint Inhibitors and Chemotherapy before Definitive Chemoradiation Therapy for Patients with Bulky Unresectable Stage III Non-small-cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Jan 6:S0360-3016(22)03693.
    PubMed     Abstract available


  74. SUR R, Pond G, Falkson C, Pan M, et al
    BRACHY: A Randomized Trial to Evaluate Symptom Improvement in Advanced Non-Small Cell Lung Cancer treated with External Beam Radiation With or Without High Dose Rate Intraluminal Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2023 Jan 4:S0360-3016(22)03703.
    PubMed     Abstract available


    December 2022
  75. LI Y, Fan X, Yu Q, Zhai H, et al
    Proton and Carbon Ion Radiotherapy Decreased Severe Lymphopenia by Reducing Thoracic Vertebra and Aortic Dose in Non-small Cell Lung Cancer versus Intensity Modulated Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2022 Dec 28:S0360-3016(22)03677.
    PubMed     Abstract available


  76. FELDMAN J
    The Future of Treating Oligometastatic Lung Cancer Is Personalized Care.
    Int J Radiat Oncol Biol Phys. 2022;114:822-823.
    PubMed    


  77. SINGER L, Scholey J
    Finding Resonance: Using MRI to Improve the Care of Oligometastatic Disease.
    Int J Radiat Oncol Biol Phys. 2022;114:936-940.
    PubMed    


  78. TSAI CJ
    Moving Away From Counting the Numbers: Leveraging a Sensible Clinical Trial Design for Oligometastatic Disease and Beyond.
    Int J Radiat Oncol Biol Phys. 2022;114:846-848.
    PubMed    


  79. KATIPALLY RR, Olson AC, Chmura SJ
    Flipping the Null: Lessons From Breast Cancer and Recalibrating Expectations in Oligometastases.
    Int J Radiat Oncol Biol Phys. 2022;114:840-842.
    PubMed    


  80. IYENGAR P
    Local Therapy for Oligometastatic Disease-Cart Before the Horse?
    Int J Radiat Oncol Biol Phys. 2022;114:836-839.
    PubMed    


  81. SHER DJ, Chen RC
    The Cost-Effectiveness of Consolidative Radiation Therapy in Oligometastatic Disease: High-Value Proposition or Wishful Thinking?
    Int J Radiat Oncol Biol Phys. 2022;114:824-826.
    PubMed    


  82. LEE JJB, Suh YJ, Oh C, Lee BM, et al
    Automated Computer-Aided Detection of Lung Nodules in Metastatic Colorectal Cancer Patients for the Identification of Pulmonary Oligometastatic Disease.
    Int J Radiat Oncol Biol Phys. 2022;114:1045-1052.
    PubMed     Abstract available


  83. BAKER S, Mou B, Jiang W, Liu M, et al
    Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial.
    Int J Radiat Oncol Biol Phys. 2022;114:856-861.
    PubMed     Abstract available


  84. CHEN H, Badellino S, Biswas T, Dagan R, et al
    Conditional Survival of Patients With Extracranial Oligometastatic Treated With Stereotactic Body Radiation Therapy: An International Consortium Study.
    Int J Radiat Oncol Biol Phys. 2022;114:902-909.
    PubMed     Abstract available


  85. SIVA S, Jones G, Bressel M, Shaw M, et al
    Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases.
    Int J Radiat Oncol Biol Phys. 2022;114:862-870.
    PubMed     Abstract available


  86. WILLMANN J, Vlaskou Badra E, Adilovic S, Christ SM, et al
    Distant Metastasis Velocity as a Novel Prognostic Score for Overall Survival After Disease Progression Following Stereotactic Body Radiation Therapy for Oligometastatic Disease.
    Int J Radiat Oncol Biol Phys. 2022;114:871-882.
    PubMed     Abstract available


  87. SHERRY AD, Bathala TK, Liu S, Fellman BM, et al
    Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND.
    Int J Radiat Oncol Biol Phys. 2022;114:910-918.
    PubMed     Abstract available


  88. VERMA V, Yegya-Raman N, Sprave T, Han G, et al
    A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases.
    Int J Radiat Oncol Biol Phys. 2022;114:977-988.
    PubMed     Abstract available


  89. CHEN H, Poon I, Atenafu EG, Badellino S, et al
    Development of a Prognostic Model for Overall Survival in Patients With Extracranial Oligometastatic Disease Treated With Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2022;114:892-901.
    PubMed     Abstract available


    November 2022
  90. TRAN PT, Sutera P, Phillips RM, Deek MP, et al
    From Idea to Clinical Practice: A Brief History of Oligometastatic Disease.
    Int J Radiat Oncol Biol Phys. 2022;114:576-580.
    PubMed    


  91. OLADERU OT, Yerramilli D
    Aggressive Local Control of Oligorecurrence After Oligometastasis: A Tale of Competing Risk Management.
    Int J Radiat Oncol Biol Phys. 2022;114:573-574.
    PubMed    


  92. GOODMAN CR, Strauss JB
    One Way or Another: An Oligorecurrence After an Oligometastasis of an Estrogen Receptor-Positive Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2022;114:571-572.
    PubMed    


  93. NAVARRIA P, Baldaccini D, Clerici E, Marini B, et al
    Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study.
    Int J Radiat Oncol Biol Phys. 2022;114:762-770.
    PubMed     Abstract available


  94. KORPICS MC, Katipally RR, Partouche J, Cutright D, et al
    Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy.
    Int J Radiat Oncol Biol Phys. 2022;114:645-654.
    PubMed     Abstract available


  95. NEVENS D, Jongen A, Kindts I, Billiet C, et al
    Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
    Int J Radiat Oncol Biol Phys. 2022;114:587-595.
    PubMed     Abstract available


  96. GUTKIN PM, von Eyben R, Chin A, Donaldson SS, et al
    Local Control Outcomes Using Stereotactic Body Radiation Therapy or Surgical Resection for Metastatic Sarcoma.
    Int J Radiat Oncol Biol Phys. 2022;114:771-779.
    PubMed     Abstract available


  97. MAHMOOD U, Huynh MA, Killoran JH, Qian JM, et al
    Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade.
    Int J Radiat Oncol Biol Phys. 2022;114:666-675.
    PubMed     Abstract available


  98. ZHAI D, Huang J, Hu Y, Wan C, et al
    Ionizing Radiation-Induced Tumor Cell-Derived Microparticles Prevent Lung Metastasis by Remodeling the Pulmonary Immune Microenvironment.
    Int J Radiat Oncol Biol Phys. 2022;114:502-515.
    PubMed     Abstract available


    October 2022
  99. ARCIDIACONO F, Anselmo P, Casale M, Zannori C, et al
    STereotactic Ablative RadioTherapy in NEWly diagnosed and recurrent locally advanced non-small cell lung cancer patients unfit for concurrEnt RAdio-chemotherapy: early analysis of the START-NEW-ERA non-randomised phase II trial.
    Int J Radiat Oncol Biol Phys. 2022 Oct 23. pii: S0360-3016(22)03459.
    PubMed     Abstract available


  100. KIM YH, Ahn SJ, Moon SH, Kim JH, et al
    Randomized, multicenter, phase III study of accelerated fraction radiotherapy with concomitant boost to the gross tumor volume compared with conventional fractionation in concurrent chemoradiation in patients with unresectable stage III non-small cell
    Int J Radiat Oncol Biol Phys. 2022 Oct 21. pii: S0360-3016(22)03440.
    PubMed     Abstract available


    September 2022
  101. OWEN D, Siva S, Salama JK, Robinson C, et al
    If at First You Don't Succeed-Stereotactic Body Radiation Therapy for Recurrent Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2022;114:5-9.
    PubMed    


    August 2022
  102. HUANG YS, Chen JL, Lan HT, Tai MH, et al
    Xenon-enhanced Ventilation CT for Functional Lung Avoidance Radiotherapy in Patients with Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Aug 24. pii: S0360-3016(22)00754.
    PubMed     Abstract available


  103. WANG S, Mahon R, Weiss E, Jan N, et al
    Automated Lung Cancer Segmentation Using a PET and CT Dual-Modality Deep Learning Neural Network.
    Int J Radiat Oncol Biol Phys. 2022 Aug 4. pii: S0360-3016(22)03067.
    PubMed     Abstract available


  104. YAREMKO BP, Capaldi DPI, Sheikh K, Palma DA, et al
    Functional Lung Avoidance for Individualized Radiation Therapy: Results of a Double-Masked, Randomized Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2022;113:1072-1084.
    PubMed     Abstract available


  105. KOLAHDOUZAN K, Chavoshi M, Bayani R, Darzikolaee NM, et al
    Low-Dose Whole Lung Irradiation for Treatment of COVID-19 Pneumonia: A Systematic Review and Meta-Analysis.
    Int J Radiat Oncol Biol Phys. 2022;113:946-959.
    PubMed     Abstract available


    July 2022
  106. QIU B, Xi Y, Liu F, Li Y, et al
    Gut microbiome is associated with the response to Chemoradiotherapy in Patients with Non-small cell lung Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jul 26. pii: S0360-3016(22)00749.
    PubMed     Abstract available


  107. XIANG L, Ren PR, Li HX, Ye H, et al
    Effect of three-dimensional interstitial high-dose-rate brachytherapy with regional metastatic lymph node intensity-modulated radiation therapy in locally advanced peripheral non-small cell lung cancer: 5-year follow-up of a phase II clinical trial.
    Int J Radiat Oncol Biol Phys. 2022 Jul 25. pii: S0360-3016(22)00752.
    PubMed     Abstract available


  108. KIM KH, Pyo H, Lee H, Oh D, et al
    Association of T cell senescence with radiation pneumonitis in patients with non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jul 24. pii: S0360-3016(22)00737.
    PubMed     Abstract available


  109. KUMAR S, Wang X, Pittell H, Calip GS, et al
    Real world use of radiation for newly diagnosed brain metastases in ALK-positive lung cancer receiving a first line ALK inhibitor.
    Int J Radiat Oncol Biol Phys. 2022 Jul 20. pii: S0360-3016(22)00730.
    PubMed     Abstract available


  110. LIU F, Qiu B, Xi Y, Luo Y, et al
    Efficacy of thymosin alpha1 in management of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043).
    Int J Radiat Oncol Biol Phys. 2022 Jul 20. pii: S0360-3016(22)00728.
    PubMed     Abstract available


  111. BROWNSTEIN J, Salama JK
    Moderately Hypofractionated Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: A New Way Forward for Dose Escalation?
    Int J Radiat Oncol Biol Phys. 2022;113:749-751.
    PubMed    


    June 2022
  112. CHIANG Y, Tsai YC, Wang CC, Hsueh FJ, et al
    Tumor-derived C-C motif ligand 2 (CCL2) induces the recruitment and polarization of tumor-associated macrophages and increases the metastatic potential of bladder cancer cells in the postirradiated microenvironment.
    Int J Radiat Oncol Biol Phys. 2022 Jun 9. pii: S0360-3016(22)00598.
    PubMed     Abstract available


  113. VICENTE EM, Modiri A, Kipritidis J, Yu KC, et al
    Combining Serial and Parallel Functionality in Functional Lung Avoidance Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2022;113:456-468.
    PubMed     Abstract available


  114. JAGSI R, Schipper M, Mietzel M, Pandya R, et al
    The Michigan Radiation Oncology Quality Consortium: A Novel Initiative to Improve the Quality of Radiation Oncology Care.
    Int J Radiat Oncol Biol Phys. 2022;113:257-265.
    PubMed     Abstract available


    May 2022
  115. NO HJ, Raja N, Von Eyben R, Das M, et al
    Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.
    Int J Radiat Oncol Biol Phys. 2022 May 30. pii: S0360-3016(22)00476.
    PubMed     Abstract available


  116. CHICAS-SETT R, Zafra J, Rodriguez-Abreu D, Castilla-Martinez J, et al
    Combination of Stereotactic Ablative Radiotherapy With Anti-PD-1 in Oligoprogressive Non-Small-Cell Lung Cancer And Melanoma: Results of a Prospective Multicenter Observational Study.
    Int J Radiat Oncol Biol Phys. 2022 May 17. pii: S0360-3016(22)00421.
    PubMed     Abstract available


    April 2022
  117. BRYANT AK, Sankar K, Strohbehn GW, Zhao L, et al
    Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab.
    Int J Radiat Oncol Biol Phys. 2022 Apr 18. pii: S0360-3016(22)00248.
    PubMed     Abstract available


  118. ROBINSON C, Kruser TJ, Owen D, Salama J, et al
    Fast and Furious: New Data Examining Accelerated Radiation Therapy for Limited-Stage Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2022;112:1067-1070.
    PubMed    


  119. SODJI QH, Ko R, von Eyben R, Owen SG, et al
    Acute and Late Esophageal Toxicity After SABR to Thoracic Tumors Near or Abutting the Esophagus.
    Int J Radiat Oncol Biol Phys. 2022;112:1144-1153.
    PubMed     Abstract available


  120. CHEN G, Kong P, Yang M, Hu W, et al
    Golgi Phosphoprotein 3 Confers Radioresistance via Stabilizing EGFR in Lung Adenocarcinoma.
    Int J Radiat Oncol Biol Phys. 2022;112:1216-1228.
    PubMed     Abstract available


    March 2022
  121. SPERDUTO PW, De B, Li J, Carpenter D, et al
    The Graded Prognostic Assessment (GPA) for Lung Cancer Patients with Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA including the Effect of Programmed Death Ligand-1 (PD-L1) and Othe
    Int J Radiat Oncol Biol Phys. 2022 Mar 21. pii: S0360-3016(22)00253.
    PubMed     Abstract available


  122. HOPPE BS, Nichols RC, Flampouri S, Pankuch M, et al
    Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A YYY Phase 1/2 Trial.
    Int J Radiat Oncol Biol Phys. 2022 Mar 16. pii: S0360-3016(22)00238.
    PubMed     Abstract available


  123. JIAO Z, Li H, Xiao Y, Dorsey J, et al
    Integration of Deep Learning Radiomics and Counts of Circulating Tumor Cells Improves Prediction of Outcomes of Early Stage NSCLC Patients Treated With Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2022;112:1045-1054.
    PubMed     Abstract available


  124. VINOGRADSKIY Y, Castillo R, Castillo E, Schubert L, et al
    Results of a Multi-Institutional Phase 2 Clinical Trial for 4DCT-Ventilation Functional Avoidance Thoracic Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2022;112:986-995.
    PubMed     Abstract available


  125. MA L, Sakamoto Y, Ando K, Fujita H, et al
    Th Balance-Related Host Genetic Background Affects the Therapeutic Effects of Combining Carbon-Ion Radiation Therapy With Dendritic Cell Immunotherapy.
    Int J Radiat Oncol Biol Phys. 2022;112:780-789.
    PubMed     Abstract available


    February 2022
  126. WU Y, Verma V, Liang F, Lin Q, et al
    Local consolidative therapy versus systemic therapy alone for metastatic non-small cell lung cancer: a systematic review and meta-analysis.
    Int J Radiat Oncol Biol Phys. 2022 Feb 20. pii: S0360-3016(22)00169.
    PubMed     Abstract available


  127. SHAVERDIAN N, Shepherd AF, Li X, Offin M, et al
    Impact of Tumor Mutational Burden and Gene Alterations Associated with Radiation-Response on Outcomes of Post-Operative Radiation Therapy in Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Feb 11. pii: S0360-3016(22)00160.
    PubMed     Abstract available


  128. ARRIETA O, Hernandez-Pedro N, Maldonado F, Ramos-Ramirez M, et al
    Nitroglycerin plus whole intracranial radiotherapy for brain metastases in non-small cell lung cancer patients: A randomized, open-label, phase II clinical trial.
    Int J Radiat Oncol Biol Phys. 2022 Feb 11. pii: S0360-3016(22)00156.
    PubMed     Abstract available


  129. KIM KH, Pyo H, Oh HLD, Noh JM, et al
    Dynamics of circulating immune cells during chemoradiotherapy in patients with non-small cell lung cancer support earlier administration of anti-PD-1/PD-L1 therapy.
    Int J Radiat Oncol Biol Phys. 2022 Feb 9. pii: S0360-3016(22)00143.
    PubMed     Abstract available


    January 2022
  130. BRYANT AK, Sankar K, Strohbehn GW, Zhao L, et al
    Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jan 31. pii: S0360-3016(22)00002.
    PubMed     Abstract available


  131. CONTRERAS J, Srivastava A, Samson P, DeWees T, et al
    Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jan 21. pii: S0360-3016(22)00022.
    PubMed     Abstract available


    December 2021
  132. WANG Y, Zhang T, Huang Y, Li W, et al
    Real-world Safety and Efficacy of Consolidation Durvalumab after Chemoradiotherapy for Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Int J Radiat Oncol Biol Phys. 2021 Dec 26. pii: S0360-3016(21)03422.
    PubMed     Abstract available


  133. LI L, Tang S, Yin JC, Dong L, et al
    Comprehensive next-generation sequencing reveals novel predictive biomarkers of recurrence and thoracic toxicity risks following chemoradiotherapy in limited stage small-cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2021 Dec 20. pii: S0360-3016(21)03246.
    PubMed     Abstract available


  134. LEE K, Le T, Hau E, Hanna GG, et al
    A systematic review into the radiological features predicting local recurrence after stereotactic ablative body radiotherapy (SABR) in patients with non-small cell lung cancer (NSCLC): Local recurrence features of NSCLC post-SABR.
    Int J Radiat Oncol Biol Phys. 2021 Dec 5. pii: S0360-3016(21)03235.
    PubMed     Abstract available


  135. YE R, Qiao Y, Singh PK, Wang Y, et al
    High-Content Clonogenic Survival Screen to Identify Chemoradiation Sensitizers.
    Int J Radiat Oncol Biol Phys. 2021;111:e27-e37.
    PubMed     Abstract available


    November 2021
  136. UEKI K, Matsuo Y, Takeda A, Morita S, et al
    Impact of local recurrence on cause-specific death after stereotactic body radiotherapy for early-stage non-small cell lung cancer: dynamic prediction using landmark model.
    Int J Radiat Oncol Biol Phys. 2021 Nov 25. pii: S0360-3016(21)03223.
    PubMed     Abstract available


  137. WILKIE JR, Hochstedler KA, Schipper MJ, Matuszak MM, et al
    Association Between Physician and Patient Reported Symptoms in Patients Treated with Definitive Radiotherapy for Locally Advanced Lung Cancer in a Statewide Consortium.
    Int J Radiat Oncol Biol Phys. 2021 Nov 25. pii: S0360-3016(21)03222.
    PubMed     Abstract available


  138. RANKINE LJ, Wang Z, Kelsey CR, Bier E, et al
    Hyperpolarized (129)Xe Magnetic Resonance Imaging for Functional Avoidance Treatment Planning in Thoracic Radiation Therapy: A Comparison of Ventilation- and Gas Exchange-Guided Treatment Plans.
    Int J Radiat Oncol Biol Phys. 2021;111:1044-1057.
    PubMed     Abstract available


  139. BITTERMAN DS, Selesnick P, Bredfeldt J, Williams CL, et al
    Dosimetric Planning Tradeoffs to Reduce Heart Dose Using Machine Learning-Guided Decision Support Software in Patients with Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Nov 11. pii: S0360-3016(21)03117.
    PubMed     Abstract available


  140. WANG R, Wu S, Qian D, Zhang Y, et al
    A Lung Cancer Auxiliary Diagnostic Method: Deep Learning Based Mediastinal Lymphatic Partitions Segmentation for Cancer Staging.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  141. XU R, Zhang B, Tian Y
    MRI-Based Radiomics Signature for the Prediction of Response of Lung Cancer Brain Metastases After Whole-Brain Radio-Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  142. TATINENI V, O'Shea PJ, Rauf Y, Jia X, et al
    Outcomes of BRAF, MET, RET, and ROS1 Mutated Non-Small Cell Lung Cancer With Brain Metastases (NSCLCBM).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  143. TATINENI V, O'Shea PJ, Rauf Y, Jia X, et al
    Outcomes of Immune-Checkpoint Inhibitors (ICIs) and Stereotactic Radiosurgery (SRS) in Non-Small Cell Lung Cancer Brain Metastases (NSCLCBM) Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  144. PORTE J, Martin CS, Moreau TF, Massiani MA, et al
    Loco-Regional Control and Survival Outcomes After Combined Stereotactic Radiation Therapy and Immune Checkpoint Inhibitors for Brain Metastases From Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  145. LIAN Y, Tian Y
    The Clinical Study of the Effect of WBRT on Cognitive Function of Patients With Brain Metastasis of Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  146. KONG C, Zhu X, Jiang M, Song X, et al
    Anlotinib in Combination With Whole Brain Radiotherapy for Advanced Non-Small-Cell Lung Cancer With Brain Metastases Progressive or Developed After at Least One Lines of Prior Treatment.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  147. KONG T, Nichol A, Ho C, Benny A, et al
    Population-Based Analysis of Outcomes for Patients With Brain Metastases From Epidermal Growth Factor Receptor Mutation Positive Non-Small Cell Lung Cancer Treated With Tyrosine Kinase Inhibitor Alone or Combined With Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  148. GUREWITZ J, Patel D, Benjamin C, Donahue BR, et al
    Survival in Patients with >/=5 Brain Metastases From Non-Small Cell Lung Cancer Treated With Upfront Stereotactic Radiosurgery.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  149. DOHM AE, Tang J, Mills MN, Perez BA, et al
    Clinical Outcomes of Non-Small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors, EGFR Tyrosine Kinase Inhibitors, Chemotherapy and Immune Checkpoint Inhibitors, or Chemotherapy Alone.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  150. IYENGAR P, Allen BG, Kelsey CR, Holmlund J, et al
    GRECO-1: Phase 1/2 Study of Stereotactic Body Radiation Therapy (SBRT) With or Without GC4711 for Early Stage, Centrally Located or Large Non-Small Cell Lung Cancer (NSCLC).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  151. HIGGINS KA, Hu C, Stinchcombe TE, Jabbour SK, et al
    NRG Oncology/Alliance LU005: A Phase II/III Randomized Study of Chemoradiation vs. Chemoradiation Plus Atezolizumab in Limited Stage Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  152. ZHAO L, Zhou W, Yin Y, Shi M, et al
    Hypofractionated vs. Twice Daily Radiotherapy for Limited Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  153. YAN M, Sigurdson S, Greifer N, Kennedy T, et al
    A Comparison of Hypofractionated and Twice Daily Thoracic Irradiation in Limited-Stage Small Cell Lung Cancer: An Overlap Weighted Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  154. XINGWEN F, Pan L, Wang Y, Ye S, et al
    Limited Stage Small Cell Lung Cancer Patients With Complete Response After Thoracic Chemoradiotherapy Still Benefit From Prophylactic Cranial Irradiation in the MRI Era.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  155. RIMNER A, Lai V, Califano R, Jabbour SK, et al
    Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs. Concurrent Chemoradiation Therapy in Patients With Newly Diagnosed Limited-Stage Small-Cell Lung Cancer: KEYLYNK-013.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  156. LUO J, Xu C, Song J, Xiao L, et al
    Simultaneous Integrated Dose Reduction Intensity-Modulated Radiotherapy Effectively Reduces Cardiac Irradiation Dose in Limited-Stage Small-Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  157. SUN H, Huang W, Li B
    Twice-Daily Thoracic Radiotherapy by Intensity-Modulated Radiation Therapy (IMRT) or Simultaneous Integrated Boost (SIB) IMRT With Concurrent Chemotherapy for Limited-Stage Small Cell Lung Cancer Patients? A Propensity-Score Matched Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  158. MAJEED S, Aparnathi M, Song L, Weiss J, et al
    The First-in-Class UBA1 Inhibitor, TAK-243, in Combination With Radiotherapy for YAP1 and BEND3 Biomarker-Defined Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  159. KELLER A, Kim H, Beriwal S, Smith KJ, et al
    Cost-Effectiveness of Prophylactic Cranial Irradiation vs. MRI Surveillance for Extensive Stage Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  160. GROSS AJ, Kharouta MZ, Podder TK, Choi S, et al
    Role of Thoracic Radiotherapy in Extensive Stage Small Cell Lung Cancer (ES-SCLC) in the Immunotherapy Era: A National Hospital-Based Registry Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  161. FAN X, Li B, Wang S, Fan B, et al
    Prophylactic Cranial Irradiation-Related Lymphopenia Affects Progression-Free Survival in Patients With Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  162. BILLING D, Rimner A, Shepherd AF, Gelblum D, et al
    Standard vs. Higher-Dose Consolidative Thoracic Radiation in Extensive-Stage Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  163. LESTER-COLL NH, Skelly J, Vacek PM, Sprague BL, et al
    Trends and Costs of Stereotactic Body Radiation Therapy in Metastatic Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  164. ZHU F, Wang H, Ashamalla H
    Role of Adjuvant Radiation in pN1 Non-Small Cell Lung Cancer (NSCLC) Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  165. ZHOU Y, Batus M, Fidler M, Bonomi P, et al
    Adrenal Stereotactic Body Radiation Therapy in the Management of Oligometastatic Lung Cancer: Patient Selection Matters.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  166. ZHU F, Wang H, Ashamalla H
    Role of Adjuvant Radiation in pN2 Non-Small Cell Lung Cancer (NSCLC) Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  167. ZHAO Q, Wang L
    Clinical Parameters Combined With Radiomics Features to Predict the Efficacy of Immunotherapy for Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  168. YUAN M, Zhai YR, Men Y, Hui Z, et al
    Endostar (Rh-Endostatin) Enhanced the (Chemo)Radiosensitivity in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  169. YANG W, Su SF, Ouyang W, Ma Z, et al
    To Evaluate the Efficiency and Safety of Nab-paclitaxel Plus Cisplatin and Concomitant Thoracic Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  170. YANG G, Li B, Liu C
    A Prospective Phase II Clinical Study of Simultaneous Integrated Boost Radiotherapy on Stage III Local-advanced Non-Small Cell Lung Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  171. YANG L, Li B, Xu Y, Zou B, et al
    The Role of Adjuvant Chemotherapy in Patients With Stage IB Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  172. XIANG L, Wu JB
    The 3-Year Outcome of 3D High-Dose-Rate Brachytherapy in Combination With Regional Metastatic Lymph Nodes Intensity-Modulated Radiotherapy in Peripheral Locally Advanced Non-Small Cell Lung Cancer: A Phase I/II Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  173. WU L, Bi N, Wang L
    Efficacy and Safety of Thoracic Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer Patients With Pre-Existing Interstitial Lung Diseases: A Single Center Experience of 85 Cases.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  174. WEISS E, Ricco A, Mukhopadhyay ND, Gharai LR, et al
    Predictors of High-Grade Radiation Pneumonitis and Overall Survival Following Radiochemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of Lung and Heart Dose Parameters and the Impact of Treatment Technique.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  175. WESTERGAARD SA, Castillo R, Rupji M, Bell J, et al
    Sparing Functional Lung Using Optimized Volumetric Modulated Arc Therapy in Thoracic Radiation for Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  176. HALL MD, Tom MC, Kotecha R, Von Werne K, et al
    Patterns of Care in Stereotactic Body Radiation Therapy Fractionation Schedules in Non-Small Cell Lung Cancer in the United States From 2004-2016.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  177. TENG F, Wang P
    Anti-PD-1 With or Without Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  178. WANG F, D'Rummo KA, Cao Y, Huang CH, et al
    Real-World Data for Integration Strategy of Radiotherapy (RT) With Immunotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  179. TANAKA H, Ono T, Takano H, Manabe Y, et al
    Monocyte-to-Lymphocyte Ratio is a Significant Prognostic Factor for Patients With Non-Small Cell Lung Cancer Who Treated By Stereotactic Body Radiation Therapy: A Multi Institutional Study.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  180. TOMITA N, Okuda K, Hashimoto S, Murai T, et al
    Role of Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer in Borderline Patients for Surgery due to Impaired Pulmonary Function.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  181. SUN X, Men Y, Yang X, Deng L, et al
    Recurrence Dynamics After Complete Resection and Adjuvant Chemotherapy in Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  182. SUN S, Men Y, Yang X, Sun X, et al
    Risk Factors of Brain Metastases in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  183. SMITH DR, Riportella M, Shepherd AF, Guttmann DM, et al
    Safety and Effectiveness of Definitive Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer Among Older Patients: Does Frailty Matter?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  184. SHEPHERD AF, Yu A, Margaret CA, Rhyne RF, et al
    The Correlation Between Changes in Cardiac Biomarkers and Cardiac Events in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Stereotactic Body Radiation Therapy (SBRT) - Exploratory Analysis of a Phase II Study.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  185. RICHMAN AH, Patel AK, Beriwal S, Wilhite TJ, et al
    Primary Tumor Control in Stereotactic Ablative Radiation Therapy for Large (>/= 5 cm) Non-Small Cell Lung Cancer: Does It Last?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  186. QIAO EM, Voora RS, Nalawade V, Kotha NV, et al
    Evaluating Clinical Trends and Benefits of Low-Dose CT in Lung Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  187. PENNOCK MM, Halmos B, Iii WRB, Cheng H, et al
    Predictors of Early Durvalumab Discontinuation After Chemoradiotherapy for Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  188. MARAR M, Bryant AK, Nalawade V, Das M, et al
    Impact of Facility Treatment Volume on Stereotactic Ablative Radiotherapy (SABR) Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  189. MAINA P, Garg MK, Kalnicki S, Ohri N, et al
    Predictors of Missed On-Treatment Visits During Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  190. MARKAN K, Saeed A, Hamza MA, Vyfhuis MAL, et al
    Lymphopenia Assessment in Stage III Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With Proton or Photon Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  191. SU SF, Liu FL, Li Q, Hu Y, et al
    Metastatic Non-Small Cell Lung Cancer Treated With Chemotherapy Combined With Concurrent Radiation Therapy to the Primary Tumor: Characterization of Long-term Survivor and Prognostic Value of Lung Immune Prognostic Index in Two Prospective Studies.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  192. LIU H, Qiu B, Wang D, Zhang X, et al
    Dynamic 18F-FDG Total Body PET Imaging as a Predictive Marker of Induction Chemo-Immunotherapy Followed by Concurrent Chemoradiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  193. LIU KX, Sierra-Davidson K, Tyan K, Orlina LT, et al
    Clinical Outcomes After Trimodality Therapy With Dose-Escalated Neoadjuvant Intensity-Modulated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  194. CHEN N, Li Q, Wang S, Xiong M, et al
    Hypo-Fractionated Radiotherapy With Concurrent Chemotherapy (HFRT-CHT) for Locoregional Recurrence of Non-Small Cell Lung Cancer After Complete Resection: A Prospective, Single-Arm, Phase II Study (GASTO1017).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  195. LARREA L, Gonzalez V, Antonini P, Lopez E, et al
    Lattice Radiotherapy (LRT)-Spatially Fractionated Radiotherapy (SFRT): Advanced Non-Small Cell Lung Cancer (NSCLC): Early Experience.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  196. KOFFER PP, Belani N, DiPetrillo TA, Hepel JT, et al
    Risk of Pneumonitis in Patients With Stage III Non-Small Cell Lung Cancer Treated With Definitive Chemo-RT and Durvalumab Consolidation.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  197. KANG BH, Lee JH, Xue L, Son J, et al
    Prediction of Delayed Lymphopenia at the Time of Consolidation Immunotherapy After Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  198. JABBOUR SK, Cho BC, Bria E, Kato T, et al
    KEYLYNK-012: A Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Durvalumab in Unresectable, Locally Advanced, Stage III NonSmall-Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  199. IMANO N, Kimura T, Kawahara D, Kubo K, et al
    Potential Benefits of Volumetric Modulated Arc Therapy to Reduce the Incidence of Grade 2 Radiation Pneumonitis in Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  200. HU HP, Walker C, Swaminath A
    Real-World Outcomes of Chemoradiation and Consolidative Durvalumab in Unresectable Stage III Non-Small-Cell Lung Cancer - A Systematic Review.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  201. HILL C, Fu W, Hu C, Chen X, et al
    Investigating Patient-Reported Outcomes as a Tool for Assessing Risk of Developing Radiation Pneumonitis After Thoracic Radiation in Patients With Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  202. HE K, Zhang S, Pang J, Yin J, et al
    Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Toxicity and Efficacy in Non-Small-Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  203. HE K, Barsoumian HB, Yang L, Hu Y, et al
    Selective Inhibition of STAT6 With Antisense Nucleotides Enhances Systemic Antitumor Effect of Hypofractionated Radiotherapy and Anti-PD1 in Metastatic Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  204. DIAMOND BH, Shukla U, Andrea S, DiPetrillo TA, et al
    Chemoradiation vs. Radiation Alone in the Management of Inoperable cT1-T2N1 Non-Small Cell Lung Cancer, a Propensity-Weighted Hospital Database Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  205. DEVINE M, Merriott DJ, Say C, Yoo C, et al
    Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  206. DE LEO AN, Braschi EL, Morris CG, Yeung AR, et al
    No Difference in Outcomes for Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiotherapy Based on Pathologic Diagnosis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  207. CORDOVA JS, Brenneman RJ, Kang KH, Vlacich GR, et al
    Impact of ITV/GTV Ratio on Local Failure in Early Stage Non-Small Cell Lung Cancer Patients Receiving Stereotactic Ablative Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  208. COPELLA A, Deng M, Handorf E, Kumar SS, et al
    Effect of Adjuvant Chemotherapy After SBRT for Node Negative, Non-Metastatic Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  209. CHAUDHARY KR, Halmos B, Cheng H, Cheng SK, et al
    Bmi1 Resistance Pathway and Immune Checkpoint Blockade in Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  210. BOWES C, Durgin B, Thomas S, Keane FK, et al
    Esophagitis Outcomes With or Without Contralateral Esophagus Sparing in Locally Advanced Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  211. BURBURE N, Deng M, Handorf E, Kumar SS, et al
    Clinical Significance of Total Radiation Dose for Patients With Treatment Delays in Stage III Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  212. ATKINS KM, Bitterman DS, Nohria A, Aerts H, et al
    Critical Volumetric Threshold of 15 Gy Exposure to Left Coronary Arteries Predicts Major Adverse Cardiac Events and Mortality in Lung Cancer Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  213. ARBAB M, Ellsworth SG, Huang K, Edwards DM, et al
    The Association Between Radiation to the Immune System and Overall Survival and Disease Progression in Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  214. APPEL S, Lawrence Y, Goldstein JD, Bar J, et al
    Are Advanced Radiation Techniques Safe to Use in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)? Analysis Based on Pathologic Regression and Local Recurrence.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  215. ANDRAOS TY, Shirvani S, Cornwell T, Ohri N, et al
    Characterization of the Entire Metastatic Spectrum for Non-Small Cell Lung Cancer in the Immunotherapy Era.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  216. DU D, Abuali T, Ladbury CJ, Liu JR, et al
    Biologically Active Volume of Disease (BaVD) Predicts for Survival in Metastatic Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  217. AGABALOGUN T, Heiden B, Spraker MB, Badiyan SN, et al
    Post-Operative Radiation Therapy for Non-Small Cell Lung Cancer Patients With Higher Positive to Examined Lymph Node Ratio is Associated With Improved Overall Survival.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  218. YANG L, Xu ZYZ, Zhang F, Jin JY, et al
    Predicting Changes in Circulating Immune Cells During Thoracic Radiation in Patients With Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  219. CHEN Y, Yu J, Meng X
    Safety of Thoracic Radiotherapy After PD-(L)1 Inhibitor Treatment in Patients With Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  220. NI J, Wu L, Ai X, Dong X, et al
    XX (a PD-1 Inhibitor), Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony Stimulating Factor as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer: Safety Run-In Results of a Prospective, Multicenter, Phase II Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  221. BOURBONNE V, Jaouen V, Hatt M, Pradier O, et al
    Development and Validation of a Spatial Dose Pattern Based Model Predicting Acute Pulmonary Toxicity in Patients Treated With Volumetric Arc-Therapy for Locally Advanced Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  222. MONTOYA C, Spieler B, Welford SM, Dal Pra A, et al
    Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer - From Bench to Bedside.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  223. ALL S, Iyengar P, Westover KD, Choy H, et al
    Patterns of Failure in Metastatic Non-Small Cell Lung Cancer Patients After Initiation of Pembrolizumab.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  224. ABANA CO, Hu Y, Paris S, Barsoumian HB, et al
    NBTXR3 Nanoparticle With Immunoradiation Might Reshape Metastatic Tumor-Infiltrating T Cell Repertoire in Murine Lung Cancer Model.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  225. LESTER-COLL NH, Anker CJ, Atherly A, Sprague BL, et al
    Cost-Effectiveness of Intensity Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy in Stage III Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  226. SAEED NA, Lee Y, Park HSM
    Multi-Facility vs. Single-Facility Concurrent Chemoradiation for Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  227. MCGUNIGAL M, Singh T, Amarell K, Aghdam N, et al
    Association Between Travel Distance and Use of Postoperative Radiation Therapy for Incompletely Resected Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  228. MCGUNIGAL M, Amarell K, Singh T, Chou J, et al
    Predictors and Consequences of Refusing Recommended Radiation for Locally Advanced Inoperable Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  229. KANG KH, Brenneman RJ, Waters MR, Cordova JS, et al
    The Influence of Neighborhood Socioeconomic Status and Follow-up on Survival in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  230. MO A, Guha C, Guha U, Ohri N, et al
    High Tumor Mutational Burden in Rare and Complex EGFR Mutant Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  231. TANG J, Gong Y
    Synergistic Effect of Phloretin Combined With Radiotherapy on Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  232. SON C, Moey M, Naqash A, Walker P, et al
    Cardiotoxicity in Patients With Lung Cancer Receiving Thoracic Radiotherapy and Immune-Checkpoint Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  233. CHEN W, Yang L, Xu W, Liang Z, et al
    IDO Immune Status After Radiotherapy in Patients With IV Stage Non-Small Cell Lung Cancer: An Exploratory Study.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  234. TJONG MC, Doherty M, Tan H, Chan WC, et al
    Analysis of Patient Reported Outcomes for Stage IV Non-Small Cell Lung Cancer Patients in Ontario.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  235. LI ZH, Giuliani ME, Ingledew PA
    Characteristics Assessment of Online YouTube Videos on Radiotherapy for Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  236. RACHI T, Tanaka Y, Togo H, Raturi VP, et al
    Examination of Conversion Method of Dose Distribution of Lung Cancer IMRT Using Fluence Reversible Calculation Function in O-Ring Type Linac and C Type Linac.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  237. PELES O, Atya HB, Shamir R, Berger B, et al
    Segmentation of the Upper Torso for Lung Cancer TTFields Treatment Planning.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  238. COHEN JD, Sanchez-Cerro MK, Vyfhuis MAL, Patel AN, et al
    Role of Modified Frailty Index in Predicting Oncologic Outcomes From Moderately Hypofractionated Radiotherapy for Patients with Stage I-IIB Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  239. NENOFF L, Kothe A, Matter M, Amaya E, et al
    TCP and NTCP Calculations Based on Treatment Doses Instead of Planned Doses for Daily Adaptive Proton Therapy of Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  240. KIM Y, Saraf A, Iii DMM, Gainor J, et al
    Quantitative Evaluation of Normal Lung Density Changes in Non-Small Cell Lung Cancer Patients Treated With Radiotherapy and PD-1 Immune Checkpoint Inhibitors.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  241. USUI K, Ogawa K, Goto M, Sakano Y, et al
    Cycle-Generative Adversarial Network-Based Image Correction of 4-Dimensional Cone-Beam Computed Tomography for Lung Cancer Adaptive Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  242. NOID G, Tai A, Zhong H, Shah J, et al
    Lung Perfused Blood Volume Calculated From Dynamic Contrast Enhanced DECT for Radiation Treatment Planning of Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  243. ZHANG Z, Lee SH, Caruana R, Fan Y, et al
    Circulating Tumor Cell Assay Enables Prediction of Recurrence Following Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: An Interpretable Machine Learning Study.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  244. YAN M, Zhang Z, Wang R, Yu J, et al
    Predicting Response of Lung Cancer with Definitive Radiation Therapy: A Radiomics-Based Prediction Model.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  245. NESS E, Wagstaff P, Kaur M, Harris AA, et al
    Machine Learning Classifier Using Pretreatment Factors to Predict Radiation Pneumonitis Following Stereotactic Body Radiation Therapy for Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  246. CHEN N, Qiu B, Zhou Y, Luo Y, et al
    Radiomic Features of Tumor and Tumor Organismal Environment in Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy: A Retrospective Analysis of Survival Prediction.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  247. MA Z, Yongxing B, Yuan M, Yang X, et al
    Development and Validation of Deep Learning Model Based on CT Simulator Images to Predict 5-Year Recurrence of Stage IIIA-N2 Non-Small-Cell Lung Cancer Patients Treated with Surgery and Postoperative Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  248. GAINEY JC, He Y, Zhu R, Kim Y, et al
    The Predictive Power of a Deep-Learning Segmentation Based Prognostication (DESEP) Model in Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  249. QIN A, Liu G, Chen S, Zhao L, et al
    Investigate the Feasibility of Using CBCT to Assess the Dose Validation for Spot-Scanning Proton Arc (SPArc) Therapy for Advanced Staged Lung Cancer Treatment.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  250. YANG Y, Bi N, Zhang T, Wang L, et al
    Circulating Tumor DNA Dynamics Predict Prognosis of Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Definitive Chemoradiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  251. WILLIAMS TM, Welliver MX, Brownstein JM, Otterson G, et al
    A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  252. BOGART JA, Wang X, Masters G, Gao J, et al
    Mature Outcomes of 61.2 Gy Concomitant Boost (CB) Thoracic Radiotherapy (TRT) in Limited Stage Small Cell Lung Cancer (LSCLC): CALGB 30610 (Alliance) / RTOG 0538.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  253. HOSNY A, Bitterman DS, Guthier CV, Roberts H, et al
    Clinical Validation of Deep Learning Algorithms for Lung Cancer Radiotherapy Targeting.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  254. VICENTE EM, Modiri A, Kipritidis J, Hagan A, et al
    Accounting for Serial and Parallel Functionality of the Lung May Minimize Post-Radiotherapy Loss of Respiratory Function in Lung Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  255. MANNING M, Yongue C, Garikipati A, Cykert S, et al
    Overall Survival From a Prospective Multi-Institutional Trial to Resolve Black-White Disparities in the Treatment of Early Stage Breast and Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  256. FORGHANI F, Castillo R, Castillo E, Jones BL, et al
    Is Perfusion Dose-Response Different Than Ventilation Dose-Response for Lung Cancer Patients Treated With Radiotherapy?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  257. BENKHALED S, Koshariuk O, Van Esch A, Remouchamps VM, et al
    Dosimetric Impact of Intrafraction Motion During Peripheral Lung Cancer Stereotactic Radiotherapy: Is a Second Cone Beam Computed Tomography of Added Value?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  258. RYDZEWSKI NR, Buehler D, Kendziorski C, Iyer G, et al
    Immune-Depleted Phenotype in Non-Small Cell Lung Cancer Brain Metastases Predicts for Worse Overall Survival.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  259. HERR DJ, Hochstedler K, Yin H, Dess RT, et al
    Effect of Education and Standardization of Cardiac Dose Constraints on Heart Dose in Lung Cancer Patients Receiving Definitive Radiation Therapy Across a Statewide Consortium.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  260. TJONG MC, Bitterman DS, Brantley KD, Nohria A, et al
    Cardiac Radiation Dose and Patient Risk Factors for Predicting Major Adverse Cardiac Events in Lung Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  261. XI Y, Qiu B, Li Y, Xie X, et al
    Diagnostic Signatures for Lung Cancer by Gut Microbiome and Urine Metabolomics Profiling.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  262. YANG DX, Khera R, Chang E, Joel M, et al
    Comparison of Machine Learning Approaches for Missing Data Imputation Among Non-Small Cell Lung Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  263. THOR M, Shepherd AF, Apte A, Offin M, et al
    Pre-Treatment Immune-Related Markers Predict Disease Outcomes in Non-Small Cell Lung Cancer Patients Treated With Chemoradiation and Durvalumab.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  264. MITCHELL P, O'Byrne KJ, Brown C, Jurkovic H, et al
    A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  265. HU Y, Paris S, Barsoumian H, Abana CO, et al
    Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects.
    Int J Radiat Oncol Biol Phys. 2021;111:647-657.
    PubMed     Abstract available


    October 2021
  266. KOWALCHUK RO, Niranjan A, Lee CC, Yang HC, et al
    yReirradiation with stereotactic radiosurgery after local or marginal recurrence of brain metastases from previous radiosurgery.
    Int J Radiat Oncol Biol Phys. 2021 Oct 10. pii: S0360-3016(21)02904.
    PubMed     Abstract available


  267. AL-RASHDAN A
    In Regard to Small et al.
    Int J Radiat Oncol Biol Phys. 2021;111:577-578.
    PubMed    


    September 2021
  268. AMINI A, Verma V, Simone CB 2nd, Chetty IJ, et al
    American Radium Society Appropriate Use Criteria on Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Sep 24. pii: S0360-3016(21)02823.
    PubMed     Abstract available


  269. ZHU X, Wang Y, Jiang C, Li X, et al
    Radiosensitivity-specific proteomic and signaling pathway network of non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2021 Sep 7. pii: S0360-3016(21)02776.
    PubMed     Abstract available


  270. REIJMEN E, De Mey S, De Mey W, Gevaert T, et al
    Fractionated Radiation Severely Reduces the Number of CD8+ T Cells and Mature Antigen Presenting Cells Within Lung Tumors.
    Int J Radiat Oncol Biol Phys. 2021;111:272-283.
    PubMed     Abstract available


    August 2021
  271. WANG K, Malkin HE, Patchett ND, Pearlstein KA, et al
    Coronary Artery Calcifications and Cardiac Risk after Radiotherapy for Stage III Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Aug 19. pii: S0360-3016(21)02705.
    PubMed     Abstract available


  272. MEI T, Yang X, Yu Y, Tian X, et al
    Secondary infections after diagnosis of severe radiation pneumonitis (SRP) among non-small cell lung cancer patients: pathogen distributions, choice of empirical antibiotics and the value of empirical antifungal treatment.
    Int J Radiat Oncol Biol Phys. 2021 Aug 18. pii: S0360-3016(21)02710.
    PubMed     Abstract available


  273. TRAPPETTI V, Fernandez-Palomo C, Smyth L, Klein M, et al
    Synchrotron Microbeam Radiotherapy for the treatment of lung carcinoma: a pre-clinical study.
    Int J Radiat Oncol Biol Phys. 2021 Aug 5. pii: S0360-3016(21)02630.
    PubMed     Abstract available


  274. JACOBSON G, Lawrence YR, Appel S, Weiss I, et al
    Benefits of Continuous Positive Airway Pressure (CPAP) During Radiation Therapy: A Prospective Trial.
    Int J Radiat Oncol Biol Phys. 2021;110:1466-1472.
    PubMed     Abstract available


  275. NAZ S, Leiker AJ, Choudhuri R, Preston O, et al
    Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis.
    Int J Radiat Oncol Biol Phys. 2021;110:1295-1305.
    PubMed     Abstract available


  276. PRASANNA PG, Rawojc K, Guha C, Buchsbaum JC, et al
    Normal Tissue Injury Induced by Photon and Proton Therapies: Gaps and Opportunities.
    Int J Radiat Oncol Biol Phys. 2021;110:1325-1340.
    PubMed     Abstract available


    July 2021
  277. MCFARLANE MR, Hochstedler KA, Laucis AM, Sun Y, et al
    Predictors of Pneumonitis after Conventionally Fractionated Radiotherapy for Locally Advanced Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Jul 24. pii: S0360-3016(21)02561.
    PubMed     Abstract available


  278. XU T, Meng QH, Gilchrist SC, Lin SH, et al
    Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiotherapy-Induced Cardiotoxicity in Non-Small Cell Lung Cancer Patients: A Secondary Analysis of a Prospective Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2021 Jul 21. pii: S0360-3016(21)00905.
    PubMed     Abstract available


  279. SOYFER V, Gutfeld O, Shamai S, Schlocker A, et al
    COVID-19 Vaccine-Induced Radiation Recall Phenomenon.
    Int J Radiat Oncol Biol Phys. 2021;110:957-961.
    PubMed     Abstract available


  280. JIANG W, Song Y, Sun Z, Qiu J, et al
    Dosimetric Factors and Radiomics Features Within Different Regions of Interest in Planning CT Images for Improving the Prediction of Radiation Pneumonitis.
    Int J Radiat Oncol Biol Phys. 2021;110:1161-1170.
    PubMed     Abstract available


  281. QIU B, Wang D, Li Q, Wu Y, et al
    Concurrent chemoradiotherapy with or without nimotuzumab in locally advanced squamous cell lung cancer: a phase 2 randomized trial.
    Int J Radiat Oncol Biol Phys. 2021 Jul 3. pii: S0360-3016(21)00824.
    PubMed     Abstract available


  282. ALAM SR, Zhang P, Zhang SY, Chen I, et al
    Early Prediction of Acute Esophagitis for Adaptive Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;110:883-892.
    PubMed     Abstract available


    June 2021
  283. TSAO MN, Louie AV
    Radical Radiation for Large-Volume Locally Advanced Non-Small Cell Lung Cancer: Constrained by Constraints!
    Int J Radiat Oncol Biol Phys. 2021;110:261-263.
    PubMed    


  284. KRUSER TJ, Robinson C, Owen D, Salama JK, et al
    Strike or Spare? A Review of Lung-Sparing Therapies for Malignant Pleural Mesothelioma.
    Int J Radiat Oncol Biol Phys. 2021;110:257-260.
    PubMed    


  285. PARHAR R, Livergant J, Lefresne S
    Review of Palliative Radiation Therapy Patterns of Practice for Adrenal Metastases in British Columbia.
    Int J Radiat Oncol Biol Phys. 2021;110:438-443.
    PubMed     Abstract available


  286. CHUNG EJ, Kwon S, Reedy JL, White AO, et al
    IGF-1 Receptor Signaling Regulates Type II Pneumocyte Senescence and Resulting Macrophage Polarization in Lung Fibrosis.
    Int J Radiat Oncol Biol Phys. 2021;110:526-538.
    PubMed     Abstract available


  287. SCHULTKE E, Bayat S, Bartzsch S, Brauer-Krisch E, et al
    A Mouse Model for Microbeam Radiation Therapy of the Lung.
    Int J Radiat Oncol Biol Phys. 2021;110:521-525.
    PubMed     Abstract available


  288. LIU HC, Viswanath DI, Pesaresi F, Xu Y, et al
    Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1.
    Int J Radiat Oncol Biol Phys. 2021;110:492-506.
    PubMed     Abstract available


    May 2021
  289. YU F, Ni J, Zeng W, Zhou Y, et al
    Clinical value of upfront cranial radiotherapy in osimertinib-treated EGFR-mutant non-small-cell lung cancer with brain metastases.
    Int J Radiat Oncol Biol Phys. 2021 May 28. pii: S0360-3016(21)00667.
    PubMed     Abstract available


  290. VIDETIC GMM, Reddy CA, Woody NM, Stephans KL, et al
    Ten-Year Experience in Implementing Single-Fraction Lung SBRT for Medically Inoperable Early Stage Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 May 25. pii: S0360-3016(21)00658.
    PubMed     Abstract available


  291. QIU B, Li Q, Liu J, Huang Y, et al
    Moderately Hypofractionated Once-daily Compared with Twice-daily Thoracic Radiotherapy Concurrently with Etoposide and Cisplatin in Limited-stage Small-cell Lung Cancer: a Multi-center, Phase II, Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2021 May 13. pii: S0360-3016(21)00490.
    PubMed     Abstract available


  292. KIM H, Keller A, Beriwal S, Smith KJ, et al
    Cost-Effectiveness of Prophylactic Cranial Irradiation versus MRI Surveillance for Extensive Stage Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 May 10. pii: S0360-3016(21)00477.
    PubMed     Abstract available


  293. LEE P, Loo BW Jr, Biswas T, Ding GX, et al
    Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;110:160-171.
    PubMed     Abstract available


  294. KONG FS, Moiseenko V, Zhao J, Milano MT, et al
    Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?
    Int J Radiat Oncol Biol Phys. 2021;110:172-187.
    PubMed     Abstract available


    April 2021
  295. STEBER CR, Hughes RT, Urbanic J, Clark H, et al
    Long-Term Outcomes from a Phase 2 Trial of Radiofrequency Ablation Combined with External Beam Radiation Therapy for Patients with Inoperable Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Apr 28. pii: S0360-3016(21)00402.
    PubMed     Abstract available


  296. SHURYAK I, Kachnic LA, Brenner DJ
    Lung Cancer and Heart Disease Risks Associated with Low-Dose Pulmonary Radiotherapy to COVID-19 Patients with Different Background Risks.
    Int J Radiat Oncol Biol Phys. 2021 Apr 27. pii: S0360-3016(21)00379.
    PubMed     Abstract available


  297. MALDONADO F, Gonzalez-Ling A, Onate-Ocana LF, Cabrera-Miranda LA, et al
    Prophylactic Cranial Irradiation in high-risk metastatic non-small cell lung cancer patients: Quality of life and neurocognitive analysis of a randomized phase II study.
    Int J Radiat Oncol Biol Phys. 2021 Apr 26. pii: S0360-3016(21)00378.
    PubMed     Abstract available


  298. TATEISHI Y, Takeda A, Horita N, Tsurugai Y, et al
    Stereotactic body radiotherapy with a high maximum dose improves local control, cancer-specific death and overall survival in peripheral early-stage non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2021 Apr 20. pii: S0360-3016(21)00375.
    PubMed     Abstract available


  299. MENDEZ ROMERO A, Schillemans W, van Os R, Koppe F, et al
    The Dutch-Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases.
    Int J Radiat Oncol Biol Phys. 2021;109:1377-1386.
    PubMed     Abstract available


  300. VAN LIMBERGEN EJ, Hoeben A, Lieverse RIY, Houben R, et al
    Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study.
    Int J Radiat Oncol Biol Phys. 2021;109:1421-1430.
    PubMed     Abstract available


  301. TROVO M, Relevant A, Polesel J, Muraro E, et al
    Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2021;109:1368-1376.
    PubMed     Abstract available


  302. HASLETT K, Bayman N, Franks K, Groom N, et al
    Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study.
    Int J Radiat Oncol Biol Phys. 2021;109:1341-1348.
    PubMed     Abstract available


  303. THOR M, Apte A, Haq R, Iyer A, et al
    Using Auto-Segmentation to Reduce Contouring and Dose Inconsistency in Clinical Trials: The Simulated Impact on RTOG 0617.
    Int J Radiat Oncol Biol Phys. 2021;109:1619-1626.
    PubMed     Abstract available


  304. PAN T, Lu Y, Thomas MA, Liao Z, et al
    New Data-Driven Gated PET/CT Free of Misregistration Artifacts.
    Int J Radiat Oncol Biol Phys. 2021;109:1638-1646.
    PubMed     Abstract available


    March 2021
  305. HOSKIN P
    Double the Target Volumes.
    Int J Radiat Oncol Biol Phys. 2021;109:846.
    PubMed    


  306. SHAHI J, Poon I, Ung YC, Tsao M, et al
    Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
    Int J Radiat Oncol Biol Phys. 2021;109:764-774.
    PubMed     Abstract available


    February 2021
  307. DUNNE EM, Liu M
    Postoperative Stereotactic Body Radiation Therapy, Then Observe.
    Int J Radiat Oncol Biol Phys. 2021;109:316.
    PubMed    


  308. DE BARI B
    Cautious SBRT.
    Int J Radiat Oncol Biol Phys. 2021;109:315.
    PubMed    


  309. HELM A, Tinganelli W, Simoniello P, Kurosawa F, et al
    Reduction of Lung Metastases in a Mouse Osteosarcoma Model Treated With Carbon Ions and Immune Checkpoint Inhibitors.
    Int J Radiat Oncol Biol Phys. 2021;109:594-602.
    PubMed     Abstract available


  310. NAM JK, Kim AR, Choi SH, Kim JH, et al
    Pharmacologic Inhibition of HIF-1alpha Attenuates Radiation-Induced Pulmonary Fibrosis in a Preclinical Image Guided Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;109:553-566.
    PubMed     Abstract available


    January 2021
  311. SALAMA JK, Giuliani ME, Robinson CG, Daly ME, et al
    Single-fraction SBRT for Early Stage NSCLC-A Viable Option in "These Uncertain Times"?
    Int J Radiat Oncol Biol Phys. 2021;109:1-4.
    PubMed    


  312. NGUYEN C, Dietz N
    Lung Mass With Massive Hemoptysis: Treatment Without Tissue Diagnosis.
    Int J Radiat Oncol Biol Phys. 2021;109:5-6.
    PubMed    


    December 2020
  313. DETAPPE A, Mathieu C, Jin C, Agius MP, et al
    Anti-MUC1-C Antibody-Conjugated Nanoparticles Potentiate the Efficacy of Fractionated Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2020;108:1380-1389.
    PubMed     Abstract available


    November 2020
  314. VASQUEZ OSORIO EM, McCallum H, Bedair A, Faivre-Finn C, et al
    Protecting the Heart: A Practical Approach to Account for the Full Extent of Heart Motion in Radiation Therapy Planning.
    Int J Radiat Oncol Biol Phys. 2020;108:1082-1090.
    PubMed     Abstract available


  315. MCWILLIAM A, Khalifa J, Vasquez Osorio E, Banfill K, et al
    Novel Methodology to Investigate the Effect of Radiation Dose to Heart Substructures on Overall Survival.
    Int J Radiat Oncol Biol Phys. 2020;108:1073-1081.
    PubMed     Abstract available


  316. GUTIONTOV SI, Pitroda SP, Weichselbaum RR
    Oligometastasis: Past, Present, Future.
    Int J Radiat Oncol Biol Phys. 2020;108:530-538.
    PubMed     Abstract available


  317. TOMA-DASU I, Moiseenko V, Purdie TG, Carlson DJ, et al
    Recent Developments in the Prediction of Clinical Outcomes Data in Radiation Oncology.
    Int J Radiat Oncol Biol Phys. 2020;108:513-517.
    PubMed    


  318. MIRSCH J, Hintz L, Maier A, Fournier C, et al
    An Assessment of Radiation Doses From Radon Exposures Using a Mouse Model System.
    Int J Radiat Oncol Biol Phys. 2020;108:770-778.
    PubMed     Abstract available


    September 2020
  319. YIN L, Xue J, Li R, Zhou L, et al
    Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:212-224.
    PubMed     Abstract available


  320. TIAN S, Switchenko JM, Buchwald ZS, Patel PR, et al
    Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.
    Int J Radiat Oncol Biol Phys. 2020;108:304-313.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.